Alice started her scientific research career at The University of Manchester (UK), where she undertook a PhD in Molecular Genetics and Cell Biology investigating the role of bestrophin-1 in ocular ...

Methods Patients clinically suspected of bestrophinopathy were screened using multigene panel testing. All BEST1 variants were confirmed by Sanger sequencing, and validated in the families. Conclusion ...

The findings of this valuable manuscript advance our understanding of the significance of Bestrophin isoform 4 (BEST4) in suppressing colorectal cancer (CRC) progression. The authors used appropriate ...

Revised: This Reviewed Preprint has been revised by the authors in response to the previous round of peer review; the eLife assessment and the public reviews have been updated where necessary by the ...

A recently granted patent (Publication Number: US11827879B2) discloses a method for inactivating a mutant Bestrophin 1 (BEST1) allele in a cell containing both a mutant BEST1 allele and a functional ...

As part of the deal, Opus will be in charge of researching, developing, and selling new gene therapy candidates to address two adult-onset IRDs: bestrophin-1 (BEST1)-related inherited retinal ...

Opus will develop the novel gene therapy candidates to address bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP).

Opus plans on developing the two candidates, which are in the preclinical stage, for treatment of inherited retinal diseases — bestrophin-1 (BEST1)-related inherited retinal diseases and ...

Please provide your email address to receive an email when new articles are posted on . Opus Genetics has acquired the rights to develop two preclinical-stage AAV-based gene therapy product ...

Opus will develop the novel gene therapy candidates to address bestrophin-1 (BEST1)-related inherited retinal diseases and rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), ...